title: Reply to L. Cabel et al.
authors.affiliation: Kaiser Permanente Vallejo Medical Center, Kaiser Permanente Northern California, Vallejo, CA Lou.fehrenbacher@kp.org.
authors.forename: Louis
authors.initials: L
authors.lastname: Fehrenbacher
authors.affiliation: Kaiser Permanente Northern California, Oakland, CA.
authors.forename: Angela
authors.initials: A
authors.lastname: Capra
authors.affiliation: Kaiser Permanente Northern California, Oakland, CA.
authors.forename: Laurel
authors.initials: L
authors.lastname: Habel
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000737:chemistry* / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases